MTX325 in Healthy Volunteers and Patients With Parkinson’s Disease

The study evaluates Parkinson's disease in the context of assessing MTX325. The primary objective is not specified in the source data. Secondary objectives are also not specified in the source data.

The study population included patients with Parkinson's disease, with both female and male participants represented. The total number of participants was 118. The available information indicates that vulnerable participants were included. The age range was not specified in the source data. The trial population was selected from patients, and no additional details were provided regarding general health status, lifestyle considerations, or key inclusion or exclusion criteria.

The study is a Parkinson's disease trial in phase 3 and is planned as a multi-part investigation of MTX325 in healthy volunteers and patients with Parkinson's disease. The overall trial duration is estimated from 2026-06-30 to 2027-06-02. The study plan includes a screening visit to assess eligibility, followed by study visits during participation and an end-of-study visit to complete trial procedures. The purpose of these visits is to evaluate participation status and study completion. The expected length of participant involvement is not specified. Early termination may occur if eligibility criteria are not met or if study participation is otherwise discontinued.

No investigational medicinal product, comparator treatment, placebo, or other study drug was specified. No information on pharmaceutical form, dosage, route, frequency of administration, dosing schedule, or compliance monitoring was provided.

Efficacy will be assessed in the clinical trial for Parkinson's disease.